[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21

Advertisement
4. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • In the last 7 years, the prenatal diagnosis of these entities has improved.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Weissferdt A, Neuling K, English M, Arul S, McMullan D, Ely A, Bründler MA, Brown R: Peripheral primitive neuroectodermal tumor with postchemotherapy neuroblastoma-like differentiation. Pediatr Dev Pathol; 2006 May-Jun;9(3):229-33
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor with postchemotherapy neuroblastoma-like differentiation.
  • The girl was admitted to hospital with weight loss and a painless abdominal mass that on biopsy was diagnosed as a peripheral primitive neuroectodermal tumor/Ewing sarcoma (pPNET/EWS) of the soft tissue.
  • The patient underwent chemotherapy followed by surgical resection of the tumor 5 months after diagnosis.
  • The posttreatment residual viable tumor showed a morphologic appearance resembling a neuroblastoma.
  • This case is unusual in the sense of showing the typical gene fusion for pPNET/EWS both in the pretherapy sample with the typical morphological appearance of this tumor and in the posttherapy specimen showing neural differentiation suggestive of a neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Neuroblastoma / physiopathology. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / physiopathology
  • [MeSH-minor] Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 22. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Oncogene Fusion. Radiotherapy, Adjuvant. Time Factors. Tomography, X-Ray Computed. Translocation, Genetic. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944972.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


6. Kühne T, Staehelin F, Avoledo P, Tichelli A, Passweg J, Imbach P, Gratwohl A: [Single and double high-dose chemotherapy with autologous stem cell transplantation in children with advanced solid tumors: first experiences]. Schweiz Med Wochenschr; 2000 Mar 25;130(12):419-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Single and double high-dose chemotherapy with autologous stem cell transplantation in children with advanced solid tumors: first experiences].
  • [Transliterated title] Einfache und doppelte Hochdosis-Chemotherapie mit autologer Stammzelltransplantation bei Kindern mit fortgeschrittenen soliden Tumoren: erste Erfahrungen.
  • The disease-free survival of children with malignant disorders has increased impressively over the last three decades due to better understanding of tumour biology and the resultant improvement in diagnosis and therapy.
  • Children with advanced and relapsed solid tumours, such as brain tumour, alveolar rhabdomyosarcoma, Ewing's sarcoma, or neuroblastoma, have not benefited from this progress.
  • The concept of myeloablative high-dose chemotherapy (HDT) is based on the observation that certain cytostatic drugs have a steep linear dose-response curve, and thus escalating the dose may increase the tumour cell kill.
  • The interest in HDT intensified when autologous stem cells mobilised from the peripheral blood became available, in view of the possibility of increasing the cell dose, which correlates directly with the time period of haematopoietic recovery and thus reduces therapy-associated toxicity.
  • 11 children aged between 2.8 and 17.2 years with brain tumours, soft tissue sarcomas, germ-cell tumours and neuroblastomas were analysed over a 2-year-period.
  • 7 of the 11 children are in complete remission 2+ and 24+ months after HDT, 3 died of progressive disease and one child died of therapy-associated complications.
  • Painful stomatitis leading to total parenteral nutrition (9 children) and intravenous morphine therapy (6 children) was the most serious toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Parenteral Nutrition, Total. Platelet Transfusion. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10780056.001).
  • [ISSN] 0036-7672
  • [Journal-full-title] Schweizerische medizinische Wochenschrift
  • [ISO-abbreviation] Schweiz Med Wochenschr
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


7. Paulino AC, Nguyen TX, Barker JL Jr: Brain metastasis in children with sarcoma, neuroblastoma, and Wilms' tumor. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in children with sarcoma, neuroblastoma, and Wilms' tumor.
  • MATERIALS AND METHODS: The medical and tumor registry records of 611 children treated at the University of Iowa Hospitals and Clinics between 1965 and 2000 for a sarcoma, neuroblastoma, or Wilms' tumor were reviewed.
  • Brain metastasis occurred in 9 of 113 (8%) neuroblastoma, 7 of 104 (6.7%) rhabdomyosarcoma, 6 of 105 (5.7%) Ewing's sarcoma, 5 of 106 (4.7%) osteosarcoma, 2 of 83 (2.4%) nonrhabdomyosarcoma soft-tissue sarcoma, and 1 of 100 (1%) Wilms' tumor patients.
  • There were 22 male and 8 female patients, with a median age of 14 years at the time of diagnosis of brain metastasis (range 8 months-20 years).
  • Four patients were diagnosed at autopsy, whereas five had brain metastasis at initial diagnosis.
  • For the 25 children who did not have brain metastasis at initial presentation, the median interval from initial diagnosis to development of brain metastasis was 5 months (range 1-43 months).
  • Treatment for the 26 non-autopsy-diagnosed children included surgery (S), followed by postoperative radiotherapy (RT) and chemotherapy (CT) in 2, S and postoperative RT in 1, RT and CT in 16, S alone in 2, CT alone in 2, RT alone in 1, and no treatment in 2.
  • Median survival was 4 months after diagnosis of brain metastasis, with a 1-year survival rate of 11.5%.
  • CONCLUSION: Brain metastasis is uncommon in children with a diagnosis of sarcoma, neuroblastoma, or Wilms' tumor and is often accompanied by concurrent distant disease.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Neuroblastoma / secondary. Sarcoma / secondary. Wilms Tumor / secondary


8. Minard-Colin V, Orbach D, Martelli H, Bodemer C, Oberlin O: [Soft tissue tumors in neonates]. Arch Pediatr; 2009 Jul;16(7):1039-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue tumors in neonates].
  • Soft tissue tumors account for approximately 25% of neonatal tumors and are most often benign (more than 2/3 of cases).
  • Malignant soft tissue tumors are, after neuroblastoma, the second cause of cancer in neonates.
  • Chemotherapy is indicated when initial surgical removal cannot be accomplished without unacceptable morbidity.
  • Treatment is based on age-adapted chemotherapy and surgery.
  • [MeSH-major] Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Fibrosarcoma / congenital. Fibrosarcoma / diagnosis. Fibrosarcoma / genetics. Fibrosarcoma / therapy. Gene Fusion / genetics. Gene Rearrangement / genetics. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangioma / congenital. Hemangioma / diagnosis. Hemangioma / therapy. Humans. Infant, Newborn. Prognosis. Proto-Oncogene Proteins c-ets / genetics. Receptor, trkC / genetics. Repressor Proteins / genetics. Rhabdomyosarcoma / congenital. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398311.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; EC 2.7.10.1 / Receptor, trkC
  • [Number-of-references] 37
  •  go-up   go-down


9. Tanaka K, Kanai M, Yosizawa J, Yamazaki Y: A case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma. J Pediatr Surg; 2005 Mar;40(3):578-80
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • The authors report a case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • Imaging studies strongly suggested Altman type III sacrococcygeal teratoma.
  • Histopathologic examination of the tumor showed neuroblastoma.
  • The tumor disappeared completely after chemotherapy.
  • One year after diagnosis, no local recurrence or metastasis had been detected.
  • To the authors' knowledge, this is the first case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • [MeSH-major] Neuroblastoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Calcinosis / diagnosis. Colostomy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Infant, Newborn. Magnetic Resonance Imaging. Male. Phosphopyruvate Hydratase / analysis. Rectum / pathology. Rectum / surgery. Remission Induction. Sacrococcygeal Region. Subcutaneous Tissue. Synaptophysin / analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793740.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Synaptophysin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


10. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • Stage was defined by the International Neuroblastoma Staging System.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • The absence of cortical bone and extensive bone marrow metastatic involvement in a young neuroblastoma patient should cause a shift in attention to biologic prognostic markers.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


11. Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K: Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med; 2000 May-Jun;18(3):193-8
Hazardous Substances Data Bank. (L)-ASPARTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor.
  • PURPOSE: To evaluate the utility of proton magnetic resonance spectroscopy in bone and soft tissue tumors, especially whether or not the N-acetyl aspartate signal (NAA) could be recognized in neurogenic tumors.
  • MATERIALS AND METHODS: Forty-nine proton magnetic resonance spectroscopy studies were performed in 60 bone and soft tissue tumors.
  • Neuroblastoma (1/1), primitive neuroectodermal tumor (1/1), and malignant melanoma (1/1) after chemotherapy or radiotherapy did not show this signal.
  • CONCLUSIONS: The assigned signal at about 2.0-2.1 ppm was detected in a small percentage of bone and soft tissue tumors and could be suggestive of an untreated malignant tumor of neuroectodermal origin.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Bone Neoplasms / diagnosis. Magnetic Resonance Spectroscopy. Neuroectodermal Tumors / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10972550.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate
  •  go-up   go-down


12. Müller HL, Marx A, Trusen M, Schneider P, Kühl J: Disseminated malignant ectomesenchymoma (MEM): case report and review of the literature. Pediatr Hematol Oncol; 2002 Jan-Feb;19(1):9-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ectomesenchymoma (MEM) is a rare soft tissue tumor believed to arise from a pluripotent migratory neural crest cell and composed fo both a mesenchymal element and a neuroectodermal element.
  • The tumor consisted of a neuroblastoma component and a mesenchymal component with sarcomatous features.
  • Diagnosis and therapy were complicated by the histological heterogeneity of the tumor, which also influenced the clinical appearance and course in this case.
  • A literature search revealed 15 other evaluated cases that arose in soft tissue and had adequate clinicopathologic data.
  • Complete surgical resection was the mainstay of treatment, and chemotherapy also appeared to be important.
  • In patients with disseminated MEM, new therapeutic approaches such as high-dose chemotherapy followed by stem cell rescue should be considered, similar to the current strategy in patients with stage VI neuroblastoma or soft tissue sarcoma.
  • [MeSH-minor] 3-Iodobenzylguanidine. Bone Marrow Neoplasms / radionuclide imaging. Bone Marrow Neoplasms / secondary. Bone Marrow Neoplasms / therapy. Fatal Outcome. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11787870.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 13
  •  go-up   go-down


13. Krawczuk-Rybak M, Leszczyńska E, Wysocka J, Zelazowska-Rutkowska B: [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer]. Pediatr Endocrinol Diabetes Metab; 2008;14(2):99-103
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
  • INTRODUCTION: Composed anticancer treatment leads to different late effects, such as ovarian failure, causing infertility or premature menopause.
  • AIM OF THE STUDY: was to analyse ovarian function, particularly anti-mullerian hormone levels, in young females after anticancer treatment.
  • PATIENTS AND METHODS: We analysed FSH, LH, estradiol and anti-mullerian hormone (AMH) levels on days 3-5 of a menstrual cycle in thirty three cancer survivors in mean age 19.1+/-4.7 years treated in age 12.0+/-5.6 years for Hodgkin Lymphoma (HL) (n=16), nephroblastoma (n=7), soft tissue sarcoma (n=4), germinal tumor (n=3), neuroblastoma (n=2), histiocytosis (n=1).
  • Particular analysis of all cases showed higher (>2 SD) FSH levels in 8 patients: 5 patients treated for HL with radiotherapy and higher total doses of procarbazine, nitrogen mustard and vinblastine; 2 patients treated for soft tissue sarcoma and one patient for Wilms tumor (all received radiotherapy).
  • Lowered AMH levels were found in 8 patients treated with chemo- and radiotherapy (4 - for HL, 2 - for Wilms tumor and 2 - for soft tissue sarcoma).
  • CONCLUSION: Composed anticancer treatment, especially radiotherapy, leads to ovarian failure.
  • All causes and first symptoms of ovary damage should be known to the doctors who take care of the patients after anticancer treatment.
  • [MeSH-major] Anti-Mullerian Hormone / metabolism. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Infertility, Female / diagnosis. Menopause, Premature. Primary Ovarian Insufficiency / diagnosis. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / adverse effects. Female. Follicle Stimulating Hormone / metabolism. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Survivors


14. van den Berg H, van Rijn RR, Merks JH: Management of tumors of the chest wall in childhood: a review. J Pediatr Hematol Oncol; 2008 Mar;30(3):214-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest wall tumors in childhood are major challenges with respect to diagnostic workup and treatment.
  • Depending on diagnosis, staging, and age, therapy has to be tailored for each patient, which should be discussed in a multidisciplinary team setting.
  • Radical resection is in most cases the major component of treatment.
  • Use of chemotherapy depends on the diagnosis.
  • In soft-tissue tumors, previously considered to be chemotherapy insensitive, favorable results are currently reported.
  • [MeSH-major] Lymphoma / therapy. Neuroblastoma / therapy. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / therapy. Thoracic Neoplasms / therapy. Thoracic Wall / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Female. Humans. Male. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376284.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


15. Rao S, Azmy A, Carachi R: Neonatal tumours: a single-centre experience. Pediatr Surg Int; 2002 Sep;18(5-6):306-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present our experience of managing neonatal tumours in a tertiary reference centre to study the incidence, pathology and types, efficacy of treatment, and impact of antenatal diagnosis on the management in our practice in a retrospective study of case-notes and pathology reports.
  • Teratomas were the commonest type (n = 33, 40%) followed by neuroblastomas (NB) (14), renal (13), soft-tissue (10), hepatic (4), and miscellaneous tumours (2).
  • Surgery remains the mainstay of treatment.
  • Chemotherapy has also become safer.
  • Therapeutic complications were responsible for 50% of deaths before 1986; from 1986 onwards, there has been no therapy-related mortality.
  • The small numbers of neonatal tumours seen by individual centres underline the need for an international effort to optimise therapy and improve understanding of these tumours.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Kidney Neoplasms / surgery. Male. Neuroblastoma / surgery. Retrospective Studies. Soft Tissue Neoplasms / surgery. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12415344.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Gunes D, Uysal KM, Cetinkaya H, Tekin HG, Yuceer N, Sarialioglu F, Olgun N: Paravertebral malignant tumors of childhood: analysis of 28 pediatric patients. Childs Nerv Syst; 2009 Jan;25(1):63-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the clinical features and treatment results of the primary paravertebral malignant tumors (PMTs) in our department.
  • Tumor diagnoses were mostly neuroblastoma (46.4%) and soft tissue sarcomas (35.7%).
  • Others were managed by pediatric oncology: five with corticosteroids+/-chemotherapy (one unresponsive), one with radiotherapy (RT), and two with surgery for the clinical CC.
  • Surgery was tumor excision in nine, laminectomy in nine, laminotomy in one, and delayed surgery after chemotherapy in two cases.
  • In chemotherapy and surgery groups, there were neurologic sequela associated with the advanced disease at diagnosis in 38% and 37%, respectively.
  • The CC caused by PMTs should be initially managed with corticosteroids +/- chemotherapy to avoid the adverse late effects of RT and surgery.
  • [MeSH-major] Neuroblastoma / therapy. Spinal Cord Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Recovery of Function / physiology. Retrospective Studies. Sarcoma / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):183-90 [11134211.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):333-8 [12746166.001]
  • [Cites] Neurosurgery. 1991 Mar;28(3):349-52 [2011215.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Jan 1;29(1):E4-6 [14699290.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Oct;25(10):822-3 [14528110.001]
  • [Cites] Neurochirurgie. 2001 Dec;47(6):552-6 [11915614.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 15;22(4):442-51 [9055374.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Sep;20(6):457-66 [14631620.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):70-5 [1845814.001]
  • [Cites] Pediatr Neurol. 1994 Feb;10(1):40-3 [8198671.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1996;82(4):313-20 [8952911.001]
  • [Cites] J Neurosurg Pediatr. 2008 Jan;1(1):57-62 [18352804.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):383-7 [9298274.001]
  • (PMID = 18843494.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • Neuroblastoma was the commonest tumor (10 cases, 37%), of which 4 were stage I, 4 stage IV-S and 2 stage III.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • CONCLUSIONS: Diagnosis of congenital tumors is performed earlier in recent years due to the wide use of prenatal ultrasound.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • We ought to pass this message on to our colleagues in prenatal diagnosis, so parents get reliable information.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Nurzyńska-Flak J, Zawitkowska-Klaczyńska J, Katski K, Kowalczyk JR: [Central nervous system metastases in children with solid tumours]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):175-82
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis in this group was as follow: soft tissue sarcomas -- 51 patients, bone tumours -- 50.
  • Wilms' tumour -- 48, neuroblastoma (NBL) -- 36, germ cell tumours -- 33: Children with primary CNS tumours, retinoblastoma, lymphoma and rare tumours were not analysed.
  • Diagnosis of CNS metastases was confirmed by imaging studies (CT, MRI).
  • The median time from initial diagnosis to the detection of CNS metastases was 14 months.
  • One of them was also irradiated and received chemotherapy and only this child is alive and achieved complete remission.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Leiomyosarcoma / secondary. Neuroblastoma / secondary. Teratoma / secondary. Wilms Tumor / secondary

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738591.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Biopsy of the mass showed esthesioneuroblastoma (olfactory neuroblastoma).
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Pásztélyi Z, Schuler D, Czvenits E: Practice guidelines in pediatric hematooncology: implementation and survey. A possible way for medical quality assurance. Pediatr Hematol Oncol; 2000 Dec;17(8):679-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hungarian Pediatric Oncology Working Group intended to change the practice of prescribing diagnostic tests as well as to examine the possibility of introducing indicators about the time factors of medical care.
  • The examined time factors were the length of elapsed time from admittance to treatment and the length of hospital stay for different reasons (diagnosis, treatment, complications).
  • Included into this study are the new cases of 5 common groups of malignancies (acute lymphoblastic leukemia and non-Hodgkin lymphoma, osteosarcoma, soft tissue sarcoma, Wilms tumor, neuroblastoma) for a study period of 1 year.
  • Using the data provided by this questionnaire, a renewal of the protocols for each disease was made three times during the whole study period.
  • The authors intended to use their time indicators for benchmarking, to make a comparison possible between centers concerning the length of treatment, occurrence of complications, and delays in chemotherapy.
  • However, the examination of the time indicators in the most frequent disease (acute lymphoblastic leukemia, n = 73) showed inverse correlation between the number of admissions per year per center and the length of time elapsed up to the beginning of treatment.
  • This points to a need for better cooperation in small centers at the initial phase of the diagnosis.
  • [MeSH-minor] Follow-Up Studies. Humans. Hungary. Neoplasms / drug therapy. Quality Assurance, Health Care. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127400.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Perek D, Brozyna A, Dembowska-Baginska B, Stypinska M, Sojka M, Bacewicz L, Polnik D, Kalicinski P: [Tumours in newborns and infants up to three months of life. One institution experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):711-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Newborns and infants up to three months of life are a specific group of population in paediatric oncology due to immaturity of tissues and organs and rarity of neoplastic diseases in this group of patients (pts).
  • There are no strict therapeutic procedures established for these children.
  • THE AIM of our study was to examine distribution of tumours in newborns and infants up to 3 months of age treated in our institution and to present our own experience in the treatment of these patients.
  • Distribution of tumour types in newborns and babies from 1 to 3 months of age was analyzed separately.
  • Due to similar growth pattern, response to treatment and it's side effects in newborns and small infants, treatment results were evaluated for the whole group.
  • The most common diagnosis in this group was germ cell tumours (GCT) which constituted 60% of all tumours, amongst them 52% were mature teratomas (MT).
  • The second most common was neuroblastoma (NBL) 22%.
  • There were also 3 cases of soft tissue sarcomas (STS), 2 central nervous system tumours (CNS), 2 retinoblastoma (RB), 2 hepatoblastoma (HB).
  • Eleven pts underwent combined treatment of chemotherapy and surgery: 5 with stage III and IV NBL, 6 with other tumours.
  • Chemotherapy alone was administered to 7 pts in whom local advancement of disease enabled surgery and to pts with RBL.
  • One pt relapsed at age of 2 yrs 3 mths, probably at the primary site which was not visualized at primary diagnosis.
  • One pt, critically ill, died before any treatment.
  • GCT and neuroblastoma are the most common tumours in newborns and infants up to 3 months of age.
  • 2. Newborns and small infants with advanced neoplastic disease, similarly to older children can be cured with chemotherapy.
  • 3. Individual approach is warranted in newborns and small infants and treatment should be carried out in specialized centres.
  • 4. All patients who completed treatment of any tumour type should be followed up by a pediatric oncologist.
  • [MeSH-major] Infant Welfare / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317902.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement